This dual-receptor strategy represents a different pharmacological approach, not an upgrade to existing GLP-1 therapy, but rather a distinct category of weight loss medication
However, if you have started or changed the dose of any medications associated with significant weight gain in the past year, you may not be eligible to participate
(Note: Most thyroid cancers are papillary, not medullary, so its important to know what type of thyroid cancer youve had if youre exploring these medications.) If you have pancreatitis, diabetic retinopathy, gastroparesis, or gallbladder disease, its best to discuss the possible risks and benefits with your clinician
Khera R, Murad MH, Chandar AK, et al
However, he recommended pairing GLP-1s with intermittent fasting and keto, which contradicts leading expert guidance for GLP-1 patients